Geron Corporation
Clinical trials sponsored by Geron Corporation, explained in plain language.
Geron Corporation
GERN
NASDAQ
A biopharmaceutical company developing therapies for hematologic malignancies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental drug combo aims to tame bone marrow cancer Results expected Feb 2027 (estimated)